Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

Background Darolutamide is a structurally unique androgen-receptor antagonist that is
under development for the treatment of prostate cancer. We evaluated the efficacy of …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …

Lineage transitions are a central feature of prostate development, tumourigenesis and
treatment resistance. While epigenetic changes are well known to drive prostate lineage …

Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major
challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing …

Purpose: Lineage plasticity in prostate cancer—most commonly exemplified by loss of
androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation …

Bioinformatic analysis of 94 patient-derived xenografts (PDXs), cell lines, and organoids
(PCOs) identifies three intrinsic transcriptional subtypes of metastatic castration-resistant …

Prostate cancer (PCa) is primarily driven by aberrant Androgen Receptor (AR) signaling.
Although there has been substantial advancement in antiandrogen therapies, resistance to …